Related Experiment Video
Updated: Aug 14, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Estrogens, autoimmunity and the heart
1Research Laboratory, Division of Rheumatology, Department of Internal Medicine, University of Genova, Italy. mcutolo@unige.it
Insights
Hormone replacement therapy (HRT) with estrogens does not reduce cardiovascular risk in postmenopausal women and may worsen inflammation in autoimmune rheumatic diseases. Estrogen metabolites may explain these complex effects.
Area of Science:
- Rheumatology
- Cardiology
- Endocrinology
Background:
- Systemic autoimmune rheumatic diseases increase atherosclerosis and cardiovascular disease risk.
- Proposed mechanisms include lipid abnormalities, oxidative stress, and inflammation.
- Previous beliefs in estrogen's cardioprotective effects are challenged by recent trials.
Purpose of the Study:
- To investigate the role of hormone replacement therapy (HRT) in cardiovascular risk for postmenopausal women.
- To explore the complex relationship between estrogen, inflammation, and cardiovascular outcomes in rheumatic diseases.
Main Methods:
- Review of recent randomized trials on HRT and cardiovascular outcomes.
- Analysis of proposed mechanisms linking estrogen, inflammation, and atherosclerosis.
- Consideration of estrogen peripheral metabolites' roles.
Main Results:
- Recent randomized trials failed to demonstrate cardiovascular risk reduction with HRT in postmenopausal women.
- Estrogen may have an adverse, dose-related effect on inflammation, particularly in autoimmune conditions.
- Discrepancies between observational and randomized data may be linked to estrogen's inflammatory effects.
Conclusions:
- HRT's cardioprotective potential is questionable, especially in postmenopausal women.
- Estrogen may exacerbate inflammation in autoimmune rheumatic diseases, counteracting potential benefits.
- Estrogen metabolites might offer new insights into these conflicting cardiovascular findings.
Abstract:
Systemic inflammatory/autoimmune rheumatic diseases are associated with a significantly increased rate of atherosclerosis and cardiovascular disease. Several mechanisms of accelerated atherosclerosis have been proposed, including abnormal lipid and lipoprotein profiles, oxidative stress, enhanced apoptosis, thrombophilia, immune complexes and increased mononuclear cell infiltration of atherosclerotic lesions, local generation of cytokines and female estrogen deficiency. However, the widely shared enthusiasm about the cardioprotective potential of hormone replacement therapy (HRT) with estrogens, has come to an abrupt halt since very recent randomized trials failed to show a cardiovascular risk reduction in postmenopausal women. Several factors might play a role in these discrepancies, in particular, parts of the striking discrepancy between observational and randomized data have been attributed to an estrogen-mediated adverse effect on inflammation (enhancement, possibly dose-related). In fact, estrogens potentially increase the inflammatory/immune response in autoimmune rheumatic diseases. New roles for estrogen peripheral metabolites (hydroxylated) and their increased formation in inflammatory sites, might partially introduce some explanations for several apparently contrasting evidences.
Related Concept Videos
Oogenesis
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Graves' Disease I: Introduction

